- Home
- RPTX
as 05-30-2025 4:00pm EST
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
| Founded: | 2016 | Country: | Canada |
| Employees: | N/A | City: | SAINT-LAURENT |
| Market Cap: | 58.8M | IPO Year: | 2020 |
| Target Price: | $4.50 | AVG Volume (30 days): | 190.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.89 - $4.29 | Next Earning Date: | 05-13-2025 |
| Revenue: | $1,073,000 | Revenue Growth: | -98.90% |
| Revenue Growth (this year): | -80.93% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Repare Therapeutics Inc. (RPTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Forte Steve | RPTX | EVP, CHIEF FINANCIAL OFFICER | Mar 12 '25 | Sell | $1.14 | 6,884 | $7,847.76 | 54,786 | |
| Koehler Maria | RPTX | EVP, CHIEF MEDICAL OFFICER | Mar 12 '25 | Sell | $1.14 | 3,596 | $4,099.44 | 227,813 | |
| Segal Lloyd Mitchell | RPTX | PRESIDENT AND CEO | Mar 12 '25 | Sell | $1.14 | 21,179 | $24,144.06 | 124,394 | |
| Zinda Michael | RPTX | EVP, CHIEF SCIENTIFIC OFFICER | Mar 12 '25 | Sell | $1.14 | 5,611 | $6,396.54 | 80,297 |
Latest Repare Therapeutics Inc. News
RPTX Breaking Stock News: Dive into RPTX Ticker-Specific Updates for Smart Investing
Business Wire
18 days ago
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results
Pharmaceutical Technology
a month ago
Repare signs out-licensing deal with DCx Biotherapeutics
Business Wire
a month ago
Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics
Business Wire
a month ago
Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025
MT Newswires
2 months ago
Repare Therapeutics Appoints Steve Forte as CEO to Succeed Lloyd Segal
Business Wire
2 months ago
Repare Therapeutics Announces Leadership Transitions
Zacks
3 months ago
What Makes Repare Therapeutics (RPTX) a New Buy Stock
Business Wire
3 months ago
Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare RPTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RPTX Repare Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.